Ly6k Antikörper (N-Term)
Kurzübersicht für Ly6k Antikörper (N-Term) (ABIN1450086)
Target
Alle Ly6k Antikörper anzeigenReaktivität
Wirt
Klonalität
Konjugat
Applikation
-
-
Bindungsspezifität
- N-Term
-
Aufreinigung
- Affinity chromatography purified via peptide column
-
Immunogen
- Rabbit polyclonal LY6K antibody was raised against an 18 amino acid synthetic peptide near the amino terminus of Human LY6K
-
Isotyp
- IgG
-
-
-
-
Applikationshinweise
- Optimal working dilution should be determined by the investigator.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Konzentration
- 1.0 mg/mL
-
Buffer
- PBS containing 0.02 % Sodium Azide as preservative
-
Konservierungsmittel
- Sodium azide
-
Vorsichtsmaßnahmen
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handhabung
- Avoid repeated freezing and thawing.
-
Lagerung
- 4 °C/-20 °C
-
Informationen zur Lagerung
- Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
-
-
- Ly6k (Lymphocyte Antigen 6 Complex, Locus K (Ly6k))
-
Andere Bezeichnung
- LY6K
-
Hintergrund
- The lymphocyte antigen 6 complex locus K (LY6K), a member of cancer-testis antigen was initially identified as a molecular marker for head-and-neck squamous cell carcinoma as well a breast cancer. LY6K is a GPI-anchored membrane protein that is specifically associated with germ cell marker TEX101 and is strongly observed in testis, but only weakly in other tissues. LY6K mRNA was found to be upregulated in numerous bladder cancers due to gene amplification. Furthermore, knockdown experiments using LY6K siRNA reduced cell growth, migration and invasion in bladder carcinoma cell lines, suggesting that LY6K contributes to bladder cancer development.Synonyms: CO16, Ly-6K, Lymphocyte antigen 6K
-
Gen-ID
- 54742
Target
-